Editor’s Perspective: Is The Ketek Scandal Good For Big Pharma? Generic Biologic Bill Could Suffer
Executive Summary
It was not a pretty sight in Room 2123 of the Rayburn House Office Building on Feb. 12, where the House's Energy and Commerce Committee's Oversight and Investigations Subcommittee held a hearing on fraud in the studies of the antibiotic Ketek. The head of Sanofi-Aventis' U.S. R&D had to acknowledge he could not verify that other studies were free from fraud, and committee members lambasted FDA Commissioner Andrew von Eschenbach in absentia
You may also be interested in...
FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?
As FDA considers how best to address continued concerns about generics for Wellbutrin XL (bupropion extended-release tablets), one issue it may wrestle with is whether it should conduct bioequivalence studies at the highest dose, 300 mg, which has a higher risk of seizures
FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?
As FDA considers how best to address continued concerns about generics for Wellbutrin XL (bupropion extended-release tablets), one issue it may wrestle with is whether it should conduct bioequivalence studies at the highest dose, 300 mg, which has a higher risk of seizures
Ranbaxy’s Ripples: Generic Drug Integrity Returns As Focus For Congress, FDA
Problems at a drug company have once again put FDA in the crosshairs of the House Energy and Commerce Committee